WO2004089403A1 - アルブミン凝集体及び/または不純蛋白質の除去方法 - Google Patents
アルブミン凝集体及び/または不純蛋白質の除去方法 Download PDFInfo
- Publication number
- WO2004089403A1 WO2004089403A1 PCT/JP2004/005086 JP2004005086W WO2004089403A1 WO 2004089403 A1 WO2004089403 A1 WO 2004089403A1 JP 2004005086 W JP2004005086 W JP 2004005086W WO 2004089403 A1 WO2004089403 A1 WO 2004089403A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- albumin
- aggregates
- preparation
- impurities
- removal membrane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Definitions
- the present invention relates to the field of ethical drugs.
- it is related with the manufacturing method of the serum albumin formulation which is 1 type of a plasma fraction formulation, and the formulation obtained by the said method. More specifically, a method for removing albumin aggregates and / or impurities, a method for producing an albumin preparation comprising the method for removing alpmin aggregates and / or impurities during the production process, and a method for producing the albumin preparations.
- the present invention relates to an albumin preparation.
- the present invention provides a method for producing an albumin preparation that maintains a high yield on an industrial scale, and an albumin preparation with reduced albumin aggregates and / or impurities.
- Serum alpmin is a protein with a molecular weight of 66,000 Da and is an elliptical molecule consisting of 585 amino acids.
- Serum albumin is the most abundant protein in plasma, which accounts for about 60% of all proteins, and is synthesized in the liver by the liver. It is involved in maintaining plasma colloid osmotic pressure in blood, neutralizing toxins and maintaining acid-base balance, and is responsible for nonspecific binding to many drugs and compounds and transporting them.
- Albumin preparations prepared from the above-mentioned serum albumin are used for the treatment of burns, albumin loss due to Nephmouth syndrome, etc., hypoalbuminemia due to reduced albumin synthesis ability, hemorrhagic shock, and the like.
- Albumin preparations (including heated human plasma proteins) are high-concentration protein preparations with a protein concentration of 4.4 to 25% (albumin content of 80% or 96% or more).
- the volume per formulation is as large as 20 to 25 OmL, and in its production, it is required to process a large amount and a large volume of protein.
- albumin preparation is a preparation that has been exposed to a high concentration of alcohol in the alcohol fractionation process in the production process and subjected to liquid heating for 60 hours at 60 ° C for the purpose of virus inactivation. Has been demonstrated by clinical use since 50 years.
- albumin aggregates are formed in the albumin preparation through the alcohol fractionation and the heat treatment.
- the causes of the formation of albumin aggregates are as follows: (1) contact with alcohol during alcohol fractionation, (2) aggregation of albumin itself by heat treatment, (3) interaction between albumin and impure protein during heat treatment Aggregation and the like. Although there is no direct knowledge that this aggregate affects the safety of the preparation, the aggregate is a protein modification that does not originally exist in the body, so it should not be contained in the preparation. Is desirable.
- a purification method of human serum albumin a purification method usually used in protein chemistry, for example, salting-out method, ultrafiltration method, isoelectric precipitation method, ion exchange method, etc. Oral matography, gel filtration chromatography, affinity mouthmatography, etc. are selected or used in combination. Furthermore, liquid heat treatment for the purpose of virus inactivation is widely used at the final stage of the manufacturing process. It is known that a commercial albumin preparation produced by such a method contains 2 to 10% aggregates in the total protein by gel filtration analysis. It is also known that impure proteins other than albumin are present in 1 to 4% of all proteins.
- Aggregates of human serum albumin are considered to be albumin aggregated by the action of impure proteins that are unstable to heat due to the liquid heat treatment described above.
- the agglomerates are formed by combining two or more monomers, and the isoelectric point is very similar in chemical properties to the monomers and is usually produced in production. Separation is difficult with the purification method. For this reason, conventional techniques combine several purification methods such as gel filtration chromatography, ion exchange chromatography, affinity mouthmatography, isoelectric focusing, ammonium sulfate fractionation, and ethanol fractionation. (See Japanese Patent Publication No. 1 1-5 0 9 5 2 5 (Patent No. 2 9 2 6 7 2 2)).
- impure proteins also contain other proteins such as haptoglobin, transferrin, and hemopexin as raw material-derived proteins, and even after these many purification steps, they are still in the final formulation. % Remaining and reducing impure protein as much as possible is an important manufacturing issue. Disclosure of the invention
- an object of the present invention is to provide a method for reducing the aggregate content in an albumin preparation and a low-resolved albumin preparation having an aggregate content.
- Albumin aggregate formed in the alcohol fraction (2) Albumin aggregate formed in the heat treatment, and (3) Albumin and impure protein interacted in the heat treatment. Broadly divided into aggregates. Therefore, the methods for reducing and removing the aggregates of anolebumin preparation are as follows: (1) reducing and removing albumin aggregates before heat treatment; (2) interacting with albumin during heating and coagulating. It was considered that the impure protein to be aggregated was reduced / removed in advance before the heat treatment, and (3) all aggregates generated after the heat treatment were reduced / removed.
- an albumin aqueous solution containing an aggregate and an impure protein is a virus removal membrane, preferably a virus removal membrane having a pore size of 10 to 20 n ni. It was found that an effect of removing albumin aggregates and / or an impure protein having a molecular weight of about 7 to 300,000 or more can be obtained by filtration using a filter, and the present invention has been completed.
- the ability to reduce and remove aggregates and impure proteins can be achieved only by a filtration step based on the principle of removal due to the difference in molecular size of the target substance, so that the composition of the chemical solution is not changed.
- Alpmin monomer can be obtained in higher yield than before, and this makes it possible to provide formulations with better safety and stability. It became.
- the albumin preparation of the present invention which has been made to solve the above-mentioned problems, is obtained by removing human serum albumin-containing aqueous solution and removing albumin aggregates and / or impure proteins contained in the aqueous solution with a virus removal membrane.
- the special process is to attach to the process.
- the virus removal membrane for removing albumin aggregates and impure proteins used in the present invention is preferably a virus removal membrane having a pore size of 10 to 20 nm.
- a virus removal membrane having a pore size of 10 to 20 nm.
- it is commercially available under the product names such as Branova 15 N (Asahi Kasei), Ultipore V FD V 20 (Paul), Pyasolve (Millipore)
- the removal film is a suitable example.
- albumin which is the main component of the preparation according to the present invention. Specifically, it is derived from mammals such as human, ushi, and rabbit, and is based on gene recombination technology. Examples include those derived from cultured cells, particularly those derived from humans, which are practical, for example, the V fraction obtained by Mr. Korn's cold alcohol fraction.
- the method for producing an albumin preparation of the present invention includes all of the methods including a step of filtering the aqueous solution containing the alpmin to a virus removal membrane to remove albumin aggregates and impure proteins. That is, it does not deviate from the technical idea of the present invention no matter which stage is included. For example, by carrying out the filtration step of the present application prior to heat treatment for virus inactivation, albumin aggregates that have already been formed or albumin aggregates by interaction with albumin during the heat treatment step are formed. Contaminating proteins can be removed, or if the filtration step is carried out after heat treatment, it is possible to reduce and remove all aggregates produced by heating.
- an aqueous solution containing albumin may be applied to an anion exchanger or a prefilter with a removal size of 35 to 200 nm before filtration of the virus removal membrane to reduce albumin aggregates and impure proteins.
- an anion exchanger or a prefilter with a removal size of 35 to 200 nm before filtration of the virus removal membrane to reduce albumin aggregates and impure proteins.
- the virus removal membrane process removes viruses that are likely to be mixed and reduces the impure protein that is an aggregate-forming factor in the heat treatment.
- An albumin preparation with a low content can be obtained. Therefore, the albumin preparation obtained by the invention of the present application is safer and more stable because the virus is inactivated by the heat treatment, the virus is removed by the virus removal membrane, and the aggregates and impure proteins are reduced. It is an excellent formulation.
- an albumin preparation can be prepared, for example, as follows.
- Anion exchanger equilibrated with acetate buffer at pH 4-5 (preferably 4.4-4.6), EC5mS / cni or less (preferably 1.5 mS / cm or less) (eg DE AE-Sepharose (Amersham ), Q-Sepharose (Amersham 'Falmasia), DEAE-Toyono Kur' (East Soichi), QAE—Toyopearl
- a pre-treated albumin-containing aqueous solution prepared in the above (2) adjusted to a protein concentration of 5 to 15 w / v% (preferably 6 to: L 0 w / v%) and pH 6 to 7.5 (preferably 6.6 to 7.2), Filter and collect using a filter capable of 35-200 nm size exclusion.
- Branova 15N (Asahi Kasei) and protein concentration 5-15w / v% (preferably 6-1 0 w / v%), and an aqueous solution containing alpmine adjusted to pH 6 to 7.5 (preferably 6.6 to 7.2) is passed through and collected.
- Treatment of the present invention Liquid passing through the virus removal membrane
- the recovered solution obtained in (4) was adjusted so that the protein concentration was 25 w / v%.
- an ultrafiltration method was used. N-acetiltliptophan sodium and caprylic acid sodium are each added to a concentration of 0.08 mmo 1 per lg of protein, resulting in a solution pH of 6.9 ⁇ 0.5, which has a pore size of 0.2 2 ⁇ Using the following filtration membrane, sterilization filtration was performed to obtain a final Balta.
- the final Balta heated at 60.0 ⁇ 0.5 ° C for 10 hours or more was aseptically dispensed into vials and sealed tightly.
- the albumin-containing aqueous solution obtained in (1) of the preparation example was adjusted to a protein concentration of 5 w / v%.
- Add N-acetyl liptophan sodium and caprylic acid sodium to 0.08 m mo 1 per lg of protein, respectively, and adjust the solution pH to 6.9 ⁇ 0.5, and this was heated to 60.0 ⁇ 0.5 ° C for 10 hours or longer, and ii) this albumin solution was applied to the virus removal membrane of the present invention (Branova 15 N, Asahi Kasei).
- the albumin solution after filtration at a constant pressure of 5 kgf / cm 2 was measured by a monomer / polymer content test (gel filtration analysis applying the Japanese Pharmacopoeia, general test method, and liquid chromatographic method), respectively. .
- the results are shown in Table 1.
- Table 1 As is clear from Table 1, the effect of removing and reducing aggregates by the virus removal membrane treatment has been clarified, and the recovery rate of alpmin monomer is 100% or more, and the aggregate removal effect can be obtained with high efficiency. There was found. table 1
- the aqueous solution containing albumin obtained by (1) of Preparation Example has a protein concentration of 8 w / V% ( And an albumin solution adjusted to pH 6.98 with a 1 w / V% sodium hydroxide solution, and ii) the albumin solution was removed from the virus removal membrane (Planova 15 N, Table 2 shows the results of the in-gel sedimentation reaction test of the albumin solution after the constant pressure filtration of 0.5 kgf / cm 2 was performed on Asahi Kasei. As is clear from Table 2, the removal effect of celluloblastin and transferrin was revealed by filtration of the virus removal membrane. Furthermore, the reduction effect of haptoglobin and hemopexin was found.
- Virus removal membrane treatment was performed prior to the heating step to remove and reduce aggregates and impure proteins, and confirmed the effect of reducing the aggregate content in the preparation after heat treatment.
- ii) Preparation examples (1) to (6) to (4) virus For the alpmin preparations obtained by removing the removal membrane treatment (untreated virus removal treatment), the monomer and polymer content tests (Japanese Pharmacopoeia, General Test Method, Liquid Chromatography Method were applied mutatis mutandis. Gel filtration analysis). The results are shown in Table 3. As is clear from Table 3, the albumin preparation with the virus removal membrane filtration of the present invention has a low dimer and multimer content and has the effect of suppressing the formation of aggregates, compared to the comparative preparation without virus removal membrane treatment. It has been found.
- Example 3 Cell mouth plasmin (CP), haptoglobin (I-I p), and transferrin (cutter f) contents in the preparations of the present invention and comparative preparations were measured. The results are shown in Table 4.
- the measurement method of the impure protein was performed by the nephrometry method. As shown in Table 4, it was found that the albumin preparation produced by the method according to the present invention had a plasma protein below the detection limit and contained very little impure protein and substantially no inclusion.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-105494 | 2003-04-09 | ||
JP2003105494A JP2006182649A (ja) | 2003-04-09 | 2003-04-09 | アルブミン凝集体及び/または不純蛋白質の除去方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004089403A1 true WO2004089403A1 (ja) | 2004-10-21 |
Family
ID=33156881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/005086 WO2004089403A1 (ja) | 2003-04-09 | 2004-04-08 | アルブミン凝集体及び/または不純蛋白質の除去方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2006182649A (ja) |
WO (1) | WO2004089403A1 (ja) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02111728A (ja) * | 1988-10-20 | 1990-04-24 | Green Cross Corp:The | アルブミン製剤及びその製造方法 |
JPH0317023A (ja) * | 1989-06-15 | 1991-01-25 | Green Cross Corp:The | アルブミン製剤及びその製法 |
JPH04234326A (ja) * | 1990-12-27 | 1992-08-24 | Green Cross Corp:The | アルブミン製剤及びその製法 |
JPH06279296A (ja) * | 1993-03-25 | 1994-10-04 | Asahi Chem Ind Co Ltd | 血漿分画製剤中から蛋白質会合物の除去方法 |
WO1998030230A1 (fr) * | 1997-01-09 | 1998-07-16 | Yoshitomi Pharmaceutical Industries, Ltd. | Compositions proteinees et procede de production |
JP2000053581A (ja) * | 1998-07-10 | 2000-02-22 | Zlb Zentrallab Blutspendedienst Slk | 減少した凝集物含量を有するタンパク質製剤の製造法および該製剤の使用 |
JP2000212097A (ja) * | 1999-01-26 | 2000-08-02 | Asahi Chem Ind Co Ltd | 伝達性海綿状脳症病原因子を除去する方法 |
JP2002535292A (ja) * | 1999-01-19 | 2002-10-22 | コモン サーヴィシス エージェンシー | 蛋白質含有液体の処理 |
JP2004089155A (ja) * | 2002-09-04 | 2004-03-25 | Akon Higuchi | タンパク質水溶液の精製方法 |
-
2003
- 2003-04-09 JP JP2003105494A patent/JP2006182649A/ja not_active Withdrawn
-
2004
- 2004-04-08 WO PCT/JP2004/005086 patent/WO2004089403A1/ja active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02111728A (ja) * | 1988-10-20 | 1990-04-24 | Green Cross Corp:The | アルブミン製剤及びその製造方法 |
JPH0317023A (ja) * | 1989-06-15 | 1991-01-25 | Green Cross Corp:The | アルブミン製剤及びその製法 |
JPH04234326A (ja) * | 1990-12-27 | 1992-08-24 | Green Cross Corp:The | アルブミン製剤及びその製法 |
JPH06279296A (ja) * | 1993-03-25 | 1994-10-04 | Asahi Chem Ind Co Ltd | 血漿分画製剤中から蛋白質会合物の除去方法 |
WO1998030230A1 (fr) * | 1997-01-09 | 1998-07-16 | Yoshitomi Pharmaceutical Industries, Ltd. | Compositions proteinees et procede de production |
JP2000053581A (ja) * | 1998-07-10 | 2000-02-22 | Zlb Zentrallab Blutspendedienst Slk | 減少した凝集物含量を有するタンパク質製剤の製造法および該製剤の使用 |
JP2002535292A (ja) * | 1999-01-19 | 2002-10-22 | コモン サーヴィシス エージェンシー | 蛋白質含有液体の処理 |
JP2000212097A (ja) * | 1999-01-26 | 2000-08-02 | Asahi Chem Ind Co Ltd | 伝達性海綿状脳症病原因子を除去する方法 |
JP2004089155A (ja) * | 2002-09-04 | 2004-03-25 | Akon Higuchi | タンパク質水溶液の精製方法 |
Non-Patent Citations (10)
Title |
---|
ANESTHESIOLOGY, vol. 44, no. 6, 1976, pages 525 - 534 * |
BROUGH H. ET AL: "Performance of a Novel Viresolve NFR Virus Filter", BIOTECHNOL. PROG., vol. 18, no. 4, 2002, pages 782 - 795, XP002980859 * |
DATABASE CAPLUS [online] 2004, HIGUCHI A. ET AL: "Effect of aggregated protein sizes on the flux of protein solution through microporous membranes", XP002980858, accession no. STN Database accession no. 2004:376769 * |
DATABASE MEDLINE [online] 1976, MARSHALL B.E. ET AL: "Effects of Intersept micropore filtration of blood on microaggregates and other constituents", XP002980861, accession no. STN Database accession no. 76204068 * |
DATABASE MEDLINE [online] 1978, MARSHALL B.E. ET AL: "Effects of Fenwal 4C2423 transfusion microfilter on microaggregates and other constituents of stored blood", XP002980860, accession no. STN Database accession no. 78118564 * |
DILEO A.J. ET AL: "Size exclusion removal of model mammalian viruses using a unique membrane system, Part 1: Membrane qualification", BIOLOGICALS, vol. 21, no. 3, 1993, pages 275 - 286, XP000670928 * |
JOURNAL OF MEMBRANE SCIENCE, vol. 236, no. 1-2, 2004, pages 137 - 144 * |
PERSSON A. ET AL: "Transmission of BSA during cross-flow microfiltration: influence of pH and salt concentration", JOURNAL OF MEMBRANE SCIENCE, vol. 223, no. 1-2, 15 September 2003 (2003-09-15), pages 11 - 21, XP004463134 * |
TATEISHI J. ET AL: "Scrapie removal using Planova virus removal filters", BIOLOGICALS, vol. 29, no. 1, 2001, pages 17 - 25, XP002285689 * |
TRANSFUSION, vol. 18, no. 1, 1978, pages 38 - 45 * |
Also Published As
Publication number | Publication date |
---|---|
JP2006182649A (ja) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5755136B2 (ja) | 高濃度モノクローナル抗体溶液中のウイルス除去方法 | |
EP1268551B1 (en) | A METHOD OF PRODUCING IgG | |
HU228076B1 (en) | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products | |
JP2008500959A (ja) | ウイルスについて安全な免疫グロブリンの製造方法 | |
AU2001273907A1 (en) | A method of producing IgG | |
TW201141879A (en) | A method to produce an immunoglobulin preparation with improved yield | |
DK152334B (da) | Fremgangsmaade til fremstilling af et intravenoest indgiveligt, pyrogenfrit, lagringsstabilt serumproteinpraeparat | |
JPH04198198A (ja) | k―カゼイングリコマクロペプチドの製造法 | |
SK287633B6 (sk) | Spôsob výroby humánneho gamaglobulínu G a humánny gamaglobulín G s inaktivovanými vírusmi | |
KR100572126B1 (ko) | 면역글로불린제제및이의제조방법 | |
KR20140031915A (ko) | 고온 단기 열처리 기구로 변형되지 않은 헤모글로빈을 중합 헤모글로빈을 포함하는 상호결합된 헤모글로빈 용액으로부터 제거하는 방법 | |
EP1037923B9 (fr) | Procede de preparation par filtration d'une solution de facteur viii securisee viralement | |
JP2001500867A (ja) | 血漿タンパク質含有薬剤の製造方法 | |
JP2000053581A (ja) | 減少した凝集物含量を有するタンパク質製剤の製造法および該製剤の使用 | |
WO2004089403A1 (ja) | アルブミン凝集体及び/または不純蛋白質の除去方法 | |
JP7194113B2 (ja) | アルブミンの精製方法 | |
US20220204556A1 (en) | Systems and methods for process scale isolation of immunoglobulin g | |
CN113831405A (zh) | 一种人血白蛋白的纯化方法 | |
JP2023506173A (ja) | タンパク質のバイオプロセス | |
CN115768789A (zh) | 用于获得包含人血浆来源的免疫球蛋白m的组合物的方法 | |
JP2008534687A (ja) | タンパク性物質からタンパク質を単離するための高分離方法及び沈殿試薬 | |
WO2007136327A1 (en) | A method of producing igg | |
CN108451942A (zh) | 一种精氨酸谷氨酸注射液药物组合物及其制备方法 | |
US20240166685A1 (en) | Systems and methods for process scale isolation of a protein | |
WO2004089402A1 (ja) | アルブミン製剤の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
122 | Ep: pct application non-entry in european phase |